Shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $99.00.
A number of research analysts have issued reports on the company. BTIG Research lifted their price objective on Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a report on Monday, July 7th. Wedbush reissued an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, July 7th. Guggenheim reaffirmed a "buy" rating and issued a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Finally, Citigroup reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Monday, July 7th.
View Our Latest Research Report on Apogee Therapeutics
Apogee Therapeutics Stock Performance
Shares of NASDAQ APGE opened at $37.24 on Tuesday. The stock has a market cap of $1.71 billion, a PE ratio of -10.34 and a beta of 1.43. The business has a fifty day moving average of $40.21 and a two-hundred day moving average of $38.08. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $63.50.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. Analysts predict that Apogee Therapeutics will post -3.09 earnings per share for the current year.
Insiders Place Their Bets
In other Apogee Therapeutics news, insider Carl Dambkowski sold 10,090 shares of the business's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total transaction of $454,958.10. Following the completion of the sale, the insider directly owned 238,998 shares of the company's stock, valued at approximately $10,776,419.82. The trade was a 4.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 15,540 shares of company stock worth $653,093. Insiders own 42.77% of the company's stock.
Institutional Trading of Apogee Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in Apogee Therapeutics by 99.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock worth $33,000 after purchasing an additional 383 shares during the last quarter. Brooklyn Investment Group bought a new stake in Apogee Therapeutics during the 1st quarter worth about $42,000. GF Fund Management CO. LTD. bought a new stake in Apogee Therapeutics during the 4th quarter worth about $43,000. AlphaQuest LLC bought a new stake in Apogee Therapeutics during the 1st quarter worth about $43,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apogee Therapeutics by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock worth $77,000 after purchasing an additional 272 shares during the last quarter. 79.04% of the stock is owned by institutional investors.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
